TechCapsules

AI-summarised brief · reviewed before publication

Drug development faces a low 6.7% approval probability, often due to poor trial design and patient retention challenges. As Phase III studies generate 5.9 million data points, artificial intelligence is transforming clinical development. Sponsors are shifting from legacy processes to predictive modelling to reduce risk and accelerate timelines. AI-driven virtual twins allow teams to optimize protocol designs, eligibility criteria, and recruitment assumptions before enrollment begins. This digital model anticipates outcomes like dropout risks and site performance, mitigating operational failures. Recent research indicates high-fidelity data can construct external control arms, particularly in oncology. In late-stage neurological studies, simulations reduced control arm sizes by up to 33%. This approach allows more participants to receive study drugs rather than placebos. By testing designs in advance, clinical teams move from static planning to structured reality. This innovation addresses inefficiencies proactively, potentially decreasing the need for mid-study protocol amendments and improving overall trial success rates.